Related Experiment Video

Updated: Feb 13, 2026

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.4K

Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia

Mary B Wire1, Xiaobin Li1, Jianping Zhang1

  • 1GlaxoSmithKline, USA.

Clinical Pharmacology and Therapeutics
|March 15, 2018
PubMed

Insights

This study developed a model to guide eltrombopag dosing for pediatric chronic immune thrombocytopenia. The model supports initial doses and titration to optimize platelet counts safely in children.

Area of Science:

  • Pharmacology
  • Pediatric Hematology
  • Clinical Pharmacology

Background:

  • Chronic immune thrombocytopenia (ITP) in pediatric patients requires careful management of platelet counts.
  • Eltrombopag is a thrombopoietin receptor agonist used to increase platelet counts.
  • Optimizing eltrombopag dosing in children is crucial for efficacy and safety.

Purpose of the Study:

  • To develop a population pharmacokinetic and pharmacodynamic (PK/PD) model for eltrombopag in pediatric patients.
  • To support initial eltrombopag dosing and dose titration strategies based on simulated plasma exposure and platelet response.
  • To establish evidence-based dosing recommendations for eltrombopag in children with chronic ITP.

Main Methods:

  • Utilized data from 168 pediatric patients (aged 1-17 years) with previously treated chronic ITP from two clinical studies.
  • Developed a life-span population PK/PD model with three PK and four PD compartments.
  • Simulated platelet counts under various starting doses and dose titration schedules.

Main Results:

  • The model supported initial eltrombopag doses: 50 mg once daily for non-Asian patients aged ≥6 years, and 25 mg once daily for Asian patients (all ages) and all patients aged 1-5 years.
  • Dose adjustments were recommended at 2-week intervals to achieve target platelet counts and avoid thrombocytosis.
  • Simulations facilitated the optimization of individualized dosing strategies.

Conclusions:

  • The developed PK/PD model effectively supports eltrombopag dosing and titration in pediatric patients with chronic ITP.
  • The findings provide a basis for safe and effective initial eltrombopag dosing and individualized treatment adjustments in children.
  • This modeling approach aids in minimizing time to target platelet counts while mitigating risks like thrombocytosis.

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.4K
Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training09:15

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Published on: February 10, 2022

4.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
277
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
246
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
310